Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke

European Heart Journal

Volumn 33, Issue 22, 2012, Pages 2804-2812

  Böhm, Michael ^a   Cotton, Daniel ^b   Foster, Lydia ^c   Custodis, Florian ^a   Laufs, Ulrich ^a   Sacco, Ralph ^d   Bath, Philip M W ^e   Yusuf, Salim ^f   Diener, Hans Christoph ^g  

^a SAARLAND UNIVERSITY   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cardiovascular outcomes; Cognitive decline; Dementia; Heart rate; Stroke

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BLOOD PRESSURE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; DISABILITY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART RATE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MORTALITY; NERVOUS SYSTEM; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANKIN SCALE; RECURRENT DISEASE; REST; TRANSIENT ISCHEMIC ATTACK;

AGED; ARRHYTHMIAS, CARDIAC; COGNITION DISORDERS; DISABLED PERSONS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; RECURRENCE; STROKE;

EID: 84869127972     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs250     Document Type: Article

References (29)

1. Kannel WB, Kannel C, Paffenbarger RSJR, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-1494. (Pubitemid 17092823)
2. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/tran-dolapril Study (INVEST). Eur Heart J 2008;29:1327-1334. (Pubitemid 351768127)
3. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
4. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M. Heart rate reduction in cardiovascular therapy. Clin Res Cardiol 2011; 100:11-19.
5. Böhm M, Swedberg K, Komajda M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; on behalf of the SHIFT investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-894.
6. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:2377-2387. (Pubitemid 351653554)
7. Custodis F, Gertz K, Balkaya M, Prinz V, Mathar I, Stamm C, Kronenberg G, Kazakov A, Freichel M, Böhm M, Endres M, Laufs U. Heart rate contributes to the vascular effects of chronic mental stress: effects of endothelial function and ischemic brain injury in mice. Stroke 2011;42:1742-1749.
8. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-276.
9. Rashid P, Leonard-Bree J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34:2741-2748. (Pubitemid 37392777)
10. Ovbiagele B, Diener HC, Yusuf S, Martin R, Cotton D, Vinisko R, Donnan G, Bath P; for the PROFESS investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011;306:2137-2144.
11. Diener HC, Sacco RL, Yusuf S; for the Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomised, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368-380. (Pubitemid 46742325)
12. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-1237.
13. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus Clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-1251.
14. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus Clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischae-mic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875-884.
15. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
16. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010;31:2271-2279.
17. Nauman J, Janszky I, Vatten L, Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011;306:2579-2587.
18. Stevo J, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauser B, Zappe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685-692.
19. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Devereux RB. Effect of changing heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol 2012;109:699-704.
20. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients. The life study. Circ Arrhythmia Electrophysiol 2008;1:337-343.
21. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
22. Custodis F, Schirmer S, Baumhäkel M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010;56:1973-1983.
23. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974. (Pubitemid 40695027)
24. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482. (Pubitemid 32917338)
25. Levine JH. Rest rate and life expectancy. J Am Coll Cardiol 1997;30:1104-1106.
26. Coburn FA, Ross MG, Rivera MS. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A/J Mouse. Hopkins Med 1971;128:169-193.
27. Baumhäkel M, Custodis F, Schlimmer N, Laufs U, Böhm M. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 2010;212:55-62.
28. Schirmer SH, Degen A, Baumhäkel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kapp R, Maack C, Böhm M, Laufs U. Heart rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J 2012;33:1223-1231.
29. Balkaya M, Prinz V, Custodis F, Gertz K, Kronenberg G, Kroeber J, Fink K, Plehm R, Gass P, Laufs U, Endres M. Stress worsens endothelial function and is-chemic stroke via glucocorticoids. Stroke 2011;42:3258-3264.